

# Hemochromatosis Gene Sequence Deviations in German Patients with Porphyria Cutanea Tarda

J. FRANK<sup>1,2</sup>, P. POBLETE-GUTIÉRREZ<sup>1</sup>, R. WEISKIRCHEN<sup>3</sup>, O. GRESSNER<sup>5</sup>, H. F. MERK<sup>4</sup>, F. LAMMERT<sup>5</sup>

<sup>1</sup>Department of Dermatology, University Hospital Maastricht, The Netherlands, <sup>2</sup>Porphyria Center Aachen, University Hospital of the RWTH, Aachen, Germany, <sup>3</sup>Institute of Clinical Chemistry and Pathobiochemistry, University Hospital of the RWTH, Aachen, Germany, <sup>4</sup>Department of Dermatology and Allergology, University Hospital of the RWTH, Aachen, Germany, <sup>5</sup>Department of Medicine I, University Hospital Bonn, University of Bonn, Bonn, Germany

Received October 24, 2005

Accepted March 24, 2006

---

## Summary

Patients with porphyria cutanea tarda (PCT) reveal a susceptibility to reversible inactivation of hepatic uroporphyrinogen decarboxylase, which might be triggered by alcohol, hepatitis C virus infection, and iron overload. Inherited factors that may predispose to clinically overt PCT also include sequence deviations in the *HFE* gene that is mutated in classical hemochromatosis. Here, we studied the prevalence of both common and rare hemochromatosis gene variations in 51 PCT patients and 54 healthy controls of German origin. The frequency of the common *HFE* gene mutation C282Y was 15.7 % in PCT patients and 2.8 % in healthy control individuals ( $P < 0.001$ ). By contrast, the frequencies of the common H63D mutation did not differ, and the allele frequencies of the less frequently observed sequence deviations as substitution S65C in the *HFE* gene and mutation Y250X in the *TFR2* gene underlying hemochromatosis type 3 (*HFE3*) were  $< 0.02$  both in PCT patients and controls. Our results comprise the first molecular studies of both common and rare hemochromatosis gene variants in German PCT patients, indicating a significant role of the C282Y mutation in the pathogenesis of PCT.

---

## Key words

Porphyria cutanea tarda • Iron overload • Hemochromatosis • *HFE1* gene • *TFR2* gene • Transferrin receptor

## Introduction

The porphyrias are clinically and genetically heterogeneous metabolic diseases arising from predominantly inherited catalytic deficiencies of specific enzymes involved in heme biosynthesis. Porphyria cutanea tarda (PCT) (OMIM 176100), the most frequent

type of porphyria worldwide, results from a decreased catalytic activity of uroporphyrinogen decarboxylase (UROD), the fifth enzyme in heme biosynthesis (Bickers *et al.* 2003).

The disorder represents the only type of porphyria that is not exclusively inherited monogenetically and at least two different types can be

distinguished: acquired/sporadic (type I) PCT, in which the enzymatic deficiency is limited to the liver and inherited/familial (type II) PCT, which is inherited as an autosomal dominant trait with a decrease of enzymatic activity in all tissues (De Verneuil *et al.* 1978, Grossman *et al.* 1979). Currently, the ratio between type I and type II PCT is estimated to be approximately 3:1 to 4:1, although recent data suggest that, in some countries, the frequency of type II PCT might be much higher than previously thought (Bickers *et al.* 2003, De Verneuil *et al.* 1978, Poblete-Gutierrez *et al.* 2004).

The diagnosis of PCT is made on the basis of cutaneous manifestations, a characteristic urinary porphyrin excretion profile, and, in some laboratories, by measuring UROD activities in red blood cells. The skin findings include increased photosensitivity due to photosensitization by porphyrins and skin fragility as well as blistering, erosions, crusts, and miliae on the sun-exposed areas of the body (Fig. 1). Additionally, hyperpigmentation, hypertrichosis, sclerodermoid plaques, and scarring alopecia can be observed. Biochemically, an increased excretion of uroporphyrin (type I isomers > type III isomers), 7-carboxyl porphyrins (type III isomers > type I isomers), and coproporphyrin in the urine can be found. Enzymatically, UROD activity is decreased by approximately 50 % in red blood cells of individuals suffering from type II PCT (Bickers *et al.* 2003, De Verneuil *et al.* 1978, Grossman *et al.* 1979).

A wide range of triggering factors has been reported to precipitate the clinical manifestation of PCT, among them alcohol, estrogens, polychlorinated hydrocarbons, hemodialysis in patients with renal failure, viral infections such as hepatitis C and HIV, hepatic iron, and the inheritance of specific mutations in the *HFE* gene underlying classic hemochromatosis. Interestingly, homozygosity for the *HFE* gene mutation C282Y was found to be associated with an earlier onset of cutaneous lesions in both sporadic and familial PCT, the effect being more marked in familial PCT (Brady *et al.* 2000).

Histopathologically, 60 - 70 % of those individuals affected by PCT will develop hepatic siderosis (Uys and Eales 1963, Elder and Worwood 1998). Clinical and experimental studies suggest that UROD is reversibly inhibited by high iron concentrations (Sampietro *et al.* 1999). This is consistent with the observation that phlebotomy can lead to clinical remission and reversal of the metabolic defect (Lundvall and Weinfeld 1968, Sampietro *et al.* 1998). Several groups have studied the common *HFE* gene sequence deviations C282Y and H63D, providing evidence for increased frequencies of these molecular alterations in PCT patients from distinct ethnic origin (Hift *et al.* 1997, Roberts *et al.* 1997a, b, Santos *et al.* 1997, Stuart *et al.* 1998, Bonkovsky *et al.* 1998, Bulaj *et al.* 2000, Tannapfel *et al.* 2001, Furuyama *et al.* 1999).



**Fig. 1.** Blisters and erosions on the fingers and the back of both hands in an individual suffering from overt PCT.

Recently though, another mutation in the *HFE* gene, designated S65C, was shown to be associated with a mild form of iron overload (Mura *et al.* 1999), as indicated by significantly higher mean serum transferrin saturation in S65C heterozygotes (Beutler *et al.* 1999, 2000). In addition, a further novel mutation, designated Y250X, in the *TFR2* gene, encoding the transferrin receptor 2, was detected in a subgroup of hemochromatosis patients suffering from hemochromatosis type 3 (Camaschella *et al.* 2000).

To date, the occurrence of mutation S65C has only been reported in two PCT patients (Barton *et al.* 1999, von Ahsen *et al.* 2001), whereas the frequency of mutation Y250X in the *TFR2* gene has not been defined in PCT. Therefore, we herein sought to delineate the incidence of common and rare hemochromatosis mutations in PCT patients from Germany.

## Methods

### Patients


Diagnosis of PCT was established on the basis of cutaneous photosensitivity and typical skin symptoms on the sun exposed areas like hands, forearms and face in combination with a characteristic porphyrin excretion profile in the urine consisting of increased values for urinary uroporphyrin (ten times higher than the upper normal range, type I isomers > type III isomers), 7-carboxyl porphyrins (type III isomers > type I isomers), and coproporphyrin. Urine levels of the porphyrin precursors  $\delta$ -aminolevulinic acid and porphobilinogen were within normal ranges. Hemochromatosis genotypes were analyzed in 51 German PCT patients diagnosed and registered in the Porphyrin Center Aachen, Germany, the majority of them residing in the federal state of North-Rhine-Westphalia. For control purposes, we analyzed 54 healthy individuals without porphyria residing in the same geographical region for the occurrence of these mutations. Blood samples were collected in tubes containing ethylenediamine tetraacetic acid (EDTA). All individuals provided informed consent for inclusion in the investigation.

### Genotyping

Genomic DNA was isolated from EDTA-anticoagulated whole blood using a standard technique (QIAamp DNA Blood Kit, Qiagen, Hilden, Germany). For detection of the C282Y and H63D polymorphisms in the *HFE* gene, we employed LightCycler technology (Roche, Mannheim, Germany) essentially as described previously (Mangasser-Stephan *et al.* 1999, Tag *et al.* 2001), resulting in the genotype specific melting curves (Fig. 2A).

Likewise, the S65C mutation was detected by melting point analysis with fluorescent hybridization probes using the *HFE* H63D+S65C ToolSet for LightCycler (Genes-4U, Neftenbach, Switzerland). The assay allowed simultaneous detection of mutations H63D and S65C in the *HFE* gene by their typical melting temperatures ( $T_m$ ) (Bollhalder *et al.* 1999) (Fig. 2B).

For genotyping of mutation Y250X mutation in the *TFR2* gene, we employed direct sequencing. Primers for PCR amplification were 5'-CCC TAC AGC GCC ATC GGC-3' and 5'-GGC CCA CTG GAT CCA CGC-3' (Bulaj *et al.* 2000). For cycle sequencing, DNA (50 ng) was amplified together with 4  $\mu$ l Terminator Ready Reaction Mix (Applied Biosystems, Weiterstadt,



**Fig. 2.** Molecular analysis of the H63D, C282Y, and S65C *HFE* gene polymorphisms. (A) The derivative melting curves of the following genotypes are shown: C282/C282/H63/H63 (green), C282/Y282/H63/D63 (red), Y282/Y282/H63/H63 (black), C282/C282/D63/D63 (pink). (B) The derivative melting curves of the following genotypes are shown: H63/H63/S65/S65 (dark green), H63/D63/S65/S65 (blue), H63/H63/S65/C65 (grey). Negative controls (water) without DNA were run in parallel. The values for the respective melting temperatures varied for  $\pm 2.0$  °C between different experiments.

Germany) and 0.5 mmol primer in a total reaction volume of 20 µl for 25 cycles (96 °C/20 sec, 50 °C/20 sec, 60 °C/4 min). Products were precipitated, dissolved in 24 µl Template Suppression Reagent (Applied Biosystems), and denatured at 95 °C for 2 min. Capillary electrophoresis and data analysis were performed on the ABI PRISM 310 automated sequencer (Applied Biosystems).

### Statistics

As tests for association, we compared the distribution of alleles and genotypes in contingency tables by Pearson's goodness-of-fit  $\chi^2$  test and Armitage's trend test, respectively, using software developed by T. Wienker and T. Strom (<http://ihg.gsf.de/>). Consistency of genotype frequencies with Hardy-Weinberg equilibrium was confirmed using an exact test.

**Table 1.** Allele and genotype frequencies of common *HFE* gene mutations in 51 PCT patients and 54 controls

Mutation <sup>a</sup>		PCT Number (frequency)	Controls Number (frequency)	Tests for association Contingency table statistics
H63D	C282Y			
<i>Alleles</i>	187 C	80 (0.78)	88 (0.81)	P = 0.581
	187 G	22 (0.22)	20 (0.19)	
	845 G	86 (0.84)	105 (0.97)	
	845 A	16 (0.16)	3 (0.03)	
<i>Genotypes <sup>b</sup></i>	187 CC	20 (0.39)	34 (0.63)	OR = 6.5, 95 % CI = 1.8 - 23.1, P = 0.001
	187 CC	7 (0.14)	2 (0.04)	
	187 CC	4 (0.08)	0 (0.00)	
	187 CG	17 (0.33)	15 (0.28)	
	187 CG	1 (0.02)	1 (0.02)	
	187 GG	2 (0.04)	2 (0.04)	
	187 CC	31 (0.61)	36 (0.67)	
	187 CG	18 (0.35)	16 (0.30)	
	187 GG	2 (0.04)	2 (0.04)	
	845 GG	39 (0.76)	51 (0.94)	
	845 GA	8 (0.16)	3 (0.06)	
	845 AA	4 (0.08)	0 (0.00)	
				P = 0.578
				OR = 11.7, P = 0.005 (Armitage's trend test)

<sup>a</sup> cDNA nucleotide variant c.187C→G corresponds to amino acid substitution H63D and c.845G→A corresponds to C282Y.

<sup>b</sup> Genotype combinations not listed were not observed.

## Results

### PCT patients

Of the 51 PCT patients studied, 8 (15.7 %) were heterozygous for mutation C282Y in the *HFE* gene and 4 (7.8 %) were homozygous for this mutation (Table 1). Eighteen patients (35.3 %) were heterozygous for the H63D mutation and 2 (3.9 %) were homozygous carriers of this mutation. One patient was a compound heterozygote (C282Y/H63D).

A single PCT patient carried mutation S65C in

the heterozygous state, but neither mutation C282Y nor H63D. Automated sequencing revealed that none of the PCT patients carried mutation Y250X in the *TFR2* gene.

### Control individuals

Of the 54 healthy control individuals, 3 (5.6 %) were heterozygous for mutation C282Y, 16 (29.6 %) were heterozygous for H63D (1 compound heterozygote), and 2 (3.7 %) were homozygous for the latter mutation. One of the controls was shown to be heterozygous for mutation S65C in the *HFE* gene, and another control

carried mutation Y250X in the *TFR2* gene in the heterozygous state.

#### Statistical analysis

All genotypes were in Hardy-Weinberg equilibrium, except for the C282Y mutation in PCT patients ( $P < 0.05$ ).

Accordingly, C282Y allele frequencies were significantly higher in PCT patients compared to controls (OR 6.5, 95 % CI 1.8 - 23.1,  $P < 0.01$ , Table 1). Homozygous C282Y genotypes increased the PCT risk significantly (OR 5.2, 95 % CI 1.3 - 19.8,  $P < 0.05$ ). As determined by Armitage's trend test, the common odds ratio of the C282Y mutation was 11.7 ( $P < 0.01$ ).

Allele and genotype frequencies of the H63D, S65C, or Y250X mutations did not differ significantly between PCT patients and control individual.

## Discussion

The aim of this study was to assess the frequency of common and rare genetic alterations in the *HFE* and *TFR2* genes in association with PCT in German patients suffering from this disorder rather than evaluating the relative importance of these factors in disease pathogenesis or determining disease-specific mechanisms contributing to overt disease. Therefore, we studied the occurrence of specific sequence deviations that have all been previously reported to be associated with hemochromatosis and disturbance of iron metabolism, as PCT is an iron-dependent disease and up to 65 % of patients with PCT show an increase in total body iron stores as well as hepatic iron concentrations (Lundvall *et al.* 1970, Edwards *et al.* 1989, Fargion *et al.* 1996).

In several previous reports the association of common *HFE* gene mutations with PCT has been studied, indicating that major differences exist between allele frequencies and distributions of these sequence variants when comparing patients from different geographical background within Europe. Whereas C282Y was detected with relatively high frequencies in PCT patients from Germany, France, Hungary, Southern Italy, the Netherlands, Spain, and the United Kingdom (Roberts *et al.* 1997a, Santos *et al.* 1997, Tannapfel *et al.* 2001, Stölzel *et al.* 2003, Feder *et al.* 1996, D'Amato *et al.* 1998, Enriquez de Salamanca *et al.* 1999, Nagy *et al.* 2004, Chiaverini *et al.* 2003), a single investigation from Northern Italy revealed that the occurrence rate of this

mutation showed no differences when comparing patients suffering from PCT and healthy control individuals, whereas the frequency of H63D was significantly increased (Sampietro *et al.* 1998). Taking these data into consideration, particularly the previous studies performed on German PCT patients (Tannapfel *et al.* 2001, Stölzel *et al.* 2003), the high frequency of the C282Y *HFE* gene alleles observed in our and previous investigations in German PCT patients strongly suggest that this mutation is associated with the manifestation of overt disease in PCT, thus emphasizing that liver iron content is an important pathogenic factor in this disease. Apparently, the penetrance of mutation C282Y is much stronger than that of H63D, as reflected by the fact that individuals carrying genotype C282Y/C282Y are at much higher risk for iron overload than those with genotypes C282Y/H63D or H63D/H63D (Egger *et al.* 2002, The UK Haemochromatosis Consortium 1997, Moirand *et al.* 1999).

Beside the avoidance of well known triggering factors such as alcohol and estrogens, two major therapeutic regimens for PCT have been described: phlebotomy and low-dose chloroquine therapy. Phlebotomy leads to resolution of skin fragility and blistering within 2 - 4 months. However, normalization of urinary porphyrin concentrations usually takes longer (about 12 months). Chloroquine is thought to work by accelerating the secretion of porphyrins and may also inhibit porphyrin synthesis. The standard therapy consists of 125 mg chloroquine twice weekly, and complete remission can be expected within 6 - 9 months. Chloroquine and phlebotomy can also be used in combination in order to induce remission faster (Bickers *et al.* 2003, Lecha *et al.* 2003).

Of note, however, a recent report indicates that the genetic background of PCT patients with regard to the presence of the common *HFE* gene mutations C282Y and H63D might play a critical role in the outcome of chloroquine treatment. Whereas heterozygosity for mutation C282Y and compound heterozygosity for C282Y and H63D did not compromise the therapeutic response to chloroquine, PCT patients homozygous for C282Y seemed to retain high serum ferritin and transferrin saturation and, most importantly, failed to respond to chloroquine therapy (Stölzel *et al.* 2003).

In contrast to the two common *HFE* gene mutations C282Y and H63D, very little is known to date about the association of other mutations causing hemochromatosis and PCT. Our data indicate that the

overall prevalence rate of mutation S65C in the *HFE* gene within the German PCT population studied herein is 2.0 %, consistent with the results of previous studies performed in Denmark (Simonsen *et al.* 1999), France (Chiaverini *et al.* 2003), and the United States (Mura *et al.* 1999, Beutler *et al.* 1999), in which the prevalence ranged from 1.5 to 2.5 %. These numbers indicate that this sequence deviation does not play a crucial role in the pathogenesis of PCT, a notion that is further supported by a similar study on 47 PCT patients from Bulgaria who likewise did not display an increased frequency of mutation S65C when compared to healthy control individuals (Ivanova *et al.* 1999).

In a recent study, Lamoril and colleagues sought to evaluate a possible association between type I PCT and five different single nucleotide polymorphisms (SNPs) in the human transferrin receptor (TFRC) gene. Independent of *HFE* gene mutations C282Y, H63D, and S65C they reported an association between the IVS4+198T-allele in the TFRC gene and sporadic PCT, suggesting that type I PCT has to be considered as a multi-factorial (complex) disease, in which not only alterations in the *HFE* gene might confer susceptibility to iron overload but also other gene variants known to influence intracellular iron metabolism (Lamoril *et al.* 2002).

Based on these observations we searched for a putative association between PCT and a mutation in the *TFR2* gene, encoding the transferrin receptor 2, that has

been recently described in patients with hemochromatosis type 3 (Camaschella *et al.* 2000). This sequence variation occurs in exon 6 of *TFR2* and consists of a C-to-G transversion at nucleotide position 750 of the *TFR2* cDNA, and results in the substitution of a tyrosine residue by a premature termination codon (Y250X). *TFR2* binds transferrin, plays a critical role in cellular uptake of transferrin-bound iron in the liver, and is not down-regulated in the setting of iron overload (Kawabata *et al.* 1999, Fleming *et al.* 2000). The results of our molecular genetic studies revealed that none of the German PCT patients studied herein carried mutation Y250X in the *TFR2* gene, making an association between PCT and alterations in the transferrin receptor 2 unlikely.

In conclusion, our study in a subset of German patients suffering from PCT confirms the association between the common *HFE* mutation C282Y and PCT, and does not support a link between this disorder of heme biosynthesis and the rare *HFE* gene mutation S65C or mutation Y250X in the *TFR2* gene. The complex pathomechanisms affecting the activity of UROD and causing overt disease still remain to be defined in more detail in future studies, particularly the putative contribution of as yet unknown mutations in the *HFE* gene or in other genes involved in iron metabolism, which might promote accumulation of iron and toxic iron species, thereby contributing to inactivation of UROD.

## References

- BARTON JC, SAWADA-HIRA R, ROTHENBERG BE, ACTON RT: Two novel missense mutations of the *HFE* gene (I105T and G93R) and identification of the S65C mutation in Alabama hemochromatosis probands. *Blood Cells Mol Dis* **25**: 147-155, 1999.
- BEUTLER E, FELITTI VJ, HO NJ, GELBART T: Commentary on *HFE* S65C variant is not associated with increased transferrin saturation in voluntary blood donors by Naveen Arya, Subrata Chakrabarti, Robert A. Hegele, Paul C. Adams. *Blood Cells Mol Dis* **25**: 358-360, 1999.
- BEUTLER E, FELITTI V, GELBART T, HO N: The effect of *HFE* genotypes on measurements of iron overload in patients attending a health appraisal clinic. *Ann Intern Med* **133**: 329-337, 2000.
- BICKERS DR, FRANK J: The porphyrias. In: *Dermatology in general medicine*. TB FITZPATRICK IM, FREEDBERG, AZ EISEN, K WOLFF, KF AUSTEN, LA GOLDSMITH, SI KATZ (eds) McGraw Hill, 2003, pp 1435-1466.
- BOLLHALDER M, MURA C, LANDT O, MALY FE: LightCycler PCR assay for simultaneous detection of the H63D and S65C mutations in the *HFE* hemochromatosis gene based on opposite melting temperature shifts. *Clin Chem* **45**: 2275-2278, 1999.
- BONKOVSKY HL, POH-FITZPATRICK M, PIMSTONE N, OBANDO J, DI BISCEGLIE A, TATTRIE C, TORTORELLI K, LECLAIR P, MERCURIO MG, LAMBRECHT RW: Porphyria cutanea tarda, hepatitis C, and *HFE* gene mutations in North America. *Hepatology* **27**: 1661-1669, 1998.



- BRADY JJ, JACKSON HA, ROBERTS AG, MORGAN RR, WHATLEY SD, ROWLANDS GL, DARBY C, SHUDELL E, WATSON R, PAIKER J, WORWOOD MW, ELDER GH: Co-inheritance of mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria cutanea tarda. *J Invest Dermatol* **115**: 868-874, 2000.
- BULAJ ZJ, PHILLIPS JD, AJIOKA RS, FRANKLIN MR, GRIFFEN LM, GUINEE DJ, EDWARDS CQ, KUSHNER JP: Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. *Blood* **95**: 1565-1571, 2000.
- CAMASCHELLA C, ROETTO A, CALI A, DE GOBBI M, GAROZZO G, CARELLA M, MAJORANO N, TOTARO A, GASPARINI P: The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. *Nat Genet* **25**: 14-15, 2000.
- CHIAVERINI C, HALIMI G, OUZAN D, HALFON P, ORTONNE JP, LACOUR JP: Porphyria cutanea tarda, C282Y, H63D and S65C *HFE* gene mutations and hepatitis C infection: a study from southern France. *Dermatology* **206**: 212-216, 2003.
- D'AMATO M, MACRI A, GRISO D, BIOLCATI G, AMEGLIO F: Are His63Asp or Cys282Tyr *HFE* mutations associated with porphyria cutanea tarda? Data of patients from central and southern Italy. *J Invest Dermatol* **111**: 1241-1242, 1998.
- DE VERNEUIL H, AITKEN G, NORDMANN Y: Familial and sporadic porphyria cutanea: two different diseases. *Hum Genet* **44**: 145-151, 1978.
- EDWARDS CQ, GRIFFEN LM, GOLDFAR DE, SKOLNICK MH, KUSHNER JP: HLA-linked hemochromatosis alleles in sporadic porphyria cutanea tarda. *Gastroenterology* **97**: 972-981, 1989.
- EGGER NG, GOEGER DE, PAYNE DA, MISKOVSKY EP, WEINMAN SA, ANDERSON KE: Porphyria cutanea tarda: multiplicity of risk factors including *HFE* mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. *Dig Dis Sci* **47**: 419-426, 2002.
- ELDER GH, WORWOOD M: Mutations in the hemochromatosis gene, porphyria cutanea tarda, and iron overload. *Hepatology* **27**: 289-291, 1998.
- ENRIQUEZ DE SALAMANCA R, MORALES P, CASTRO MJ, ROJO R, GONZALEZ M, ARNAIZ-VILLENA A: The most frequent *HFE* allele linked to porphyria cutanea tarda in Mediterraneans is His63Asp. *Hepatology* **30**: 819-820, 1999.
- FARGION S, FRACANZANI AL, ROMANO R, CAPPELLINI MD, FARE M, MATTIOLI M, PIPERNO A, RONCHI G, FIORELLI G: Genetic hemochromatosis in Italian patients with porphyria cutanea tarda: possible explanation for iron overload. *J Hepatol* **24**: 564-569, 1996.
- FEDER JN, GNIRKE A, THOMAS W, TSUCHIHASHI Z, RUDDY DA, BASAVA A, DORMISHIAN F, DOMINGO R JR, ELLIS MC, FULLAN A, HINTON LM, JONES NL, KIMMEL BE, KRONMAL GS, LAUER P, LEE VK, LOEB DB, MAPA FA, McCLELLAND E, MEYER NC, MINTIER GA, MOELLER N, MOORE T, MORIKANG E, PRASS CE, QUINTANA L, STARNES SM, SCHATZMAN RC, BRUNKE KJ, DRAYNA DT, RISCH NJ, BACON BR, WOLFF RK: A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. *Nat Genet* **13**: 399-408, 1996.
- FLEMING RE, MIGAS MC, HOLDEN CC, WAHEED A, BRITTON RS, TOMATSU S, BACON BR, SLY WS: Transferrin receptor 2: continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis. *Proc Natl Acad Sci USA* **97**: 2214-2219, 2000.
- FURUYAMA K, KONDO M, HIRATA K, FUJITA H, SASSA S: Extremely rare association of *HFE* mutations with porphyria cutanea tarda in Japanese patients. *Hepatology* **30**: 1532-1533, 1999.
- GROSSMAN M E, BICKERS DR, POH-FITZPATRICK MB, DELEO VA, HARBER LC: Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients. *Am J Med* **67**: 277-286, 1979.
- HIFT RJ, CORRIGALL AV, MEISSNER PN, KIRSCH RE: Significance of HLA mutations in South African patients with porphyria cutanea tarda. *Acta Haematol* **98**: S112, 1997.
- IVANOVA A, VON AHSEN N, ADJAROV D, KRASTEV Z, OELLERICH M, WIELAND E: C282Y and H63D mutations in the *HFE* gene are not associated with porphyria cutanea tarda in Bulgaria. *Hepatology* **30**: 1531-1532, 1999.

- KAWABATA H, YANG R, HIRAMA T, VUONG PT, KAWANO S, GOMBART AF, KOEFFLER HP: Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. *J Biol Chem* **274**: 20826-20832, 1999.
- LAMORIL J, ANDANT C, GOUYA L, MALONOVA E, GRANDCHAMP B, MARTASEK P, DEYBAC JC, PUY H: Hemochromatosis (*HFE*) and transferrin receptor-1 (TFRC1) genes in sporadic porphyria cutanea tarda (sPCT). *Cell Mol Biol* **48**: 33-41, 2002.
- LECHA M: Erythropoietic protoporphyria. *Photodermatol Photoimmunol Photomed* **19**: 142-146, 2003.
- LUNDVALL O, WEINFELD A: Studies of the clinical and metabolic effects of phlebotomy treatment in porphyria cutanea tarda. *Acta Med Scand* **184**: 191-199, 1968.
- LUNDVALL O, WEINFELD A, LUNDIN P: Iron storage in porphyria cutanea tarda. *Acta Med Scand* **1-2**: 37-53, 1970.
- MANGASSER-STEPHAN K, TAG C, REISER A, GRESSNER AM: Rapid genotyping of hemochromatosis gene mutations on the LightCycler with fluorescent hybridization probes. *Clin Chem* **45**: 1875-1878, 1999.
- MOIRAND R, JOUANOLLE AM, BRISSOT P, LE GALL JY, DAVID V, DEUGNIER Y: Phenotypic expression of *HFE* mutations: a French study of 1110 unrelated iron-overloaded patients and relatives. *Gastroenterology* **116**: 372-377, 1999.
- MURA C, RAGUENES O, FEREC C: *HFE* mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. *Blood* **93**: 2502-2505, 1999.
- NAGY Z, KOSZO F, PAR A, EMRI G, HORKAY I, HORANYI M, KARADI O, RUMI G JR, MORVAY M, VARGA V, DOBOZY A, MOZSIK G: Hemochromatosis (*HFE*) gene mutations and hepatitis C virus infection as risk factors for porphyria cutanea tarda in Hungarian patients. *Liver Int* **24**: 16-20, 2004.
- POBLETE-GUTIERREZ P, MENDEZ M, WIEDERHOLT T, MERK HF, FONTANELLAS A, WOLFF C, FRANK J: The molecular basis of porphyria cutanea tarda in Chile: identification and functional characterization of mutations in the uroporphyrinogen decarboxylase gene. *Exp Dermatol* **13**: 372-379, 2004.
- ROBERTS AG, WHATLEY SD, MORGAN RR, WORWOOD M, ELDER GH: Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. *Lancet* **349**: 321-323, 1997a.
- ROBERTS AG, WHATLEY SD, NICKLIN S, WORWOOD M, POINTON JJ, STONE C, ELDER GH: The frequency of hemochromatosis-associated alleles is increased in British patients with sporadic porphyria cutanea tarda. *Hepatology* **25**: 159-161, 1997b.
- SAMPIETRO M, PIPERNO A, LUPICA L, AROSIO C, VERGANI A, CORBETTA N, MALOSIO I, MATTIOLI M, FRACANZANI AL, CAPPELLINI MD, FIORELLI G, FARGION S: High prevalence of the His63Asp *HFE* mutation in Italian patients with porphyria cutanea tarda. *Hepatology* **27**: 181-184, 1998.
- SAMPIETRO M, FIORELLI G, FARGION S: Iron overload in porphyria cutanea tarda. *Haematologica* **84**: 248-253, 1999.
- SANTOS M, CLEVERS HC, MARX JJ: Mutations of the hereditary hemochromatosis candidate gene HLA-H in porphyria cutanea tarda. *N Engl J Med* **336**: 1327-1328, 1997.
- SIMONSEN K, DISSING J, RUDBECK L, SCHWARTZ M: Rapid and simple determination of hereditary haemochromatosis mutations by multiplex PCR-SSCP: detection of a new polymorphic mutation. *Ann Hum Genet* **63**: 193-197, 1999.
- STÖLZEL U, KOSTLER E, SCHUPPAN D, RICHTER M, WOLLINA U, DOSS MO, WITTEKIND C, TANNAPFEL A: Hemochromatosis (*HFE*) gene mutations and response to chloroquine in porphyria cutanea tarda. *Arch Dermatol* **139**: 309-313, 2003.
- STUART KA, BUSFIELD F, JAZWINSKA EC, GIBSON P, BUTTERWORTH LA, COOKSLEY WG, POWELL LW, CRAWFORD DH: The C282Y mutation in the haemochromatosis gene (*HFE*) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. *J Hepatol* **28**: 404-409, 1998.
- TAG CG, GRESSNER AM, WEISKIRCHEN R: An unusual melting curve profile in LightCycler multiplex genotyping of the hemochromatosis H63D/C282Y gene mutations. *Clin Biochem* **34**: 511-515, 2001.



- TANNAPFEL A, STÖLZEL U, KOSTLER E, MELZ S, RICHTER M, KEIM V, SCHUPPAN D, WITTEKIND C: C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients. *Virchows Arch* **439**: 1-5, 2001.
- THE UK HAEMOCHROMATOSIS CONSORTIUM: A simple genetic test identifies 90 % of UK patients with haemochromatosis. *Gut* **41**: 841-844, 1997.
- UYS C, EALES L: The histopathology of the liver in acquired (symptomatic) porphyria. *S Afr J Lab Clin Med* **9**: 190-197, 1963.
- VON AHSEN N, WIELAND E, ADJAROV D, KRASTEV Z, OELLERICH M, IVANOVA A: The HFE gene S65C polymorphism is rare among Bulgarian porphyria cutanea tarda patients. *J Hepatol* **34**: 484-485, 2001.
- 

**Reprint requests**

Frank Lammert, Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Sigmund-Freud-Str. 25, D-53127 Bonn, Germany. E-mail: frank.lammert@ukb.uni-bonn.de